[Adobe]
Beyond Immatics, the upper ranks of CGT patent holders are heavily populated by U.S. organizations, particularly top-tier universities (e.g., University of California system, Harvard, MIT, and University of Pennsylvania) and research institutes. These academic centers have each amassed hundreds of CGT-related patents, reflecting the robust U.S. research ecosystem and its emphasis on cutting-edge life sciences. Meanwhile, the U.S. accounts for 62% of global CGT spending, as IQVIA has noted. To date, FDA has approved over 40 cell and gene therapy products, including first-in-class CAR-T cell therapies like Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), as well as gene therapies such as Luxturna (voretigene neparvovec-rzyl) for inherited retinal disease and Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy.
The table below highlights a broad cross-section of organizations active in CGT patents from 2020 to early September 2024:
| Organization Name | Total CGT Patents | Cell/Gene Focus % |
|---|---|---|
| Immatics Biotechnologies GmbH | 521 | 71.86 |
| University of California* | 345 | 50.00 |
| Harvard University | 288 | 67.13 |
| University of Pennsylvania | 283 | 61.12 |
| Massachusetts Institute of Technology | 256 | 71.91 |
| Illumina Inc. | 214 | 100.00 |
| Broad Institute Inc. | 187 | 68.75 |
| U.S. Department of Health & Human Services | 147 | 35.51 |
| Stanford University | 145 | 42.65 |
| ModernaTX Inc. | 140 | 96.55 |
| INSERM | 125 | 25.83 |
| Translate Bio Inc. | 117 | 94.35 |
| University of Texas | 110 | 26.38 |
| Massachusetts General Hospital | 107 | 43.15 |
| CNRS | 104 | 23.69 |
| 10x Genomics Inc. | 104 | 100.00 |
| Inscripta Inc. | 100 | 100.00 |
| University of Massachusetts | 99 | 79.84 |
| Novartis AG | 95 | 12.20 |
| Cellectis | 91 | 60.26 |
| Memorial Sloan Kettering Cancer Center | 90 | 24.93 |
| Regeneron Pharmaceuticals Inc. | 89 | 21.65 |
| Sangamo Therapeutics Inc. | 87 | 82.08 |
| Genzyme Corp. | 85 | 49.71 |
| City of Hope | 83 | 47.16 |
Note: This dataset represents an international patent corpus. Major patent jurisdictions include China (CN), Japan (JP), the United States (US), the European Patent Office (EP), Germany (DE), South Korea (KR), and the World Intellectual Property Organization (WO). The data window spanned 2020 to late August/early September 2024, depending on the jurisdiction. Patent types vary by region and include initial publications (A), granted patents (B1/B2 in the U.S.), amended patents (C), and utility models (Y). Focusing on cell and gene therapy technology, the analysis includes patents published between January 1, 2020 and September 5, 2024, filtered by grant_date ≥ 20200101. Patents are categorized by key CPC codes relevant to cell and gene therapy, including CAR-T related technologies (C12N5/0789), genetically modified cells (C12N5/0783), cell-based cancer therapies (A61K35/17 with A61P35/00), gene therapy (A61K48/00), CAR design via immunoglobulins (C07K14/725), and genetic engineering vectors (C12N15/10).
“Cell/Gene Focus %” represents the proportion of each organization’s total patents related to these therapy categories. Only organizations with at least five total patents during the specified timeframe were included.
*Encompasses the entire University of California system, including UC Berkeley, UC Davis, UC Irvine, UCLA, UC Merced, UC Riverside, UC San Diego, UC San Francisco, UC Santa Barbara, and UC Santa Cruz.
Filed Under: Cell & gene therapy
